Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles
(SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node
(SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/-
blue dye, and to evaluate MRI breast artefacts and skin staining over time.